Precision Oncology in Australia: insights from Prof David Thomas

D.ThomasD.Thomas
BulletArticle
RED 2024 C-Suite Perspectives Oncology
Share this:
Copy link

In partnership with industry and government, Omico launched the pioneering initiative PrOSPeCT in July 2023, aimed at integrating comprehensive genomic profiling (CGP) into standard oncology care in Australia. To date, Omico has provided CGP to over 15,000 patients, of whom more than 1,600 have received matched therapies primarily through accelerated access to clinical trials. Professor David Thomas, CEO of Omico, talks about the work the institution does in this talk at RED 2024.

Share this:
Copy link

More on same topic

The progress of early cancer diagnoses in clinical laboratories

Clinical mass spectrometry for therapeutic drug monitoring

Recommended topics

SequencingRED 2020Rare Diseases
Next Read
  • Artificial Intelligence, Digital Transformation, Leaders In Conversation, Management, Operations, Population Health Management
Creating a healthier Singapore with digital solutions: Q&A with Glenn Neo
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
  • C-Suite Perspectives, Leaders In Conversation, Management
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top